Anna S Schwendeman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6235186/publications.pdf

Version: 2024-02-01

83 papers 4,514 citations

147801 31 h-index 110387 64 g-index

85 all docs

85 docs citations

85 times ranked 5723 citing authors

#	Article	IF	CITATIONS
1	Designer vaccine nanodiscs for personalized cancer immunotherapy. Nature Materials, 2017, 16, 489-496.	27.5	817
2	Survey of Clinical Translation of Cancer Nanomedicinesâ€"Lessons Learned from Successes and Failures. Accounts of Chemical Research, 2019, 52, 2445-2461.	15.6	333
3	Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Science Advances, 2018, 4, eaao1736.	10.3	269
4	High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano, 2016, 10, 3015-3041.	14.6	255
5	Injectable controlled release depots for large molecules. Journal of Controlled Release, 2014, 190, 240-253.	9.9	157
6	Engineering patient-specific cancer immunotherapies. Nature Biomedical Engineering, 2019, 3, 768-782.	22.5	123
7	High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. ACS Nano, 2019, 13, 1365-1384.	14.6	122
8	High-density lipoproteins during sepsis: from bench to bedside. Critical Care, 2020, 24, 134.	5.8	110
9	Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy. Journal of Controlled Release, 2018, 282, 131-139.	9.9	104
10	Predicting drug release kinetics from nanocarriers inside dialysis bags. Journal of Controlled Release, 2019, 315, 23-30.	9.9	94
11	The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties. Journal of Lipid Research, 2015, 56, 1727-1737.	4.2	93
12	HDL in sepsis – risk factor and therapeutic approach. Frontiers in Pharmacology, 2015, 6, 244.	3.5	90
13	Battle of GLP-1 delivery technologies. Advanced Drug Delivery Reviews, 2018, 130, 113-130.	13.7	84
14	Reconstitution of the Cytb5-CytP450 Complex in Nanodiscs for Structural Studies using NMR Spectroscopy. Angewandte Chemie - International Edition, 2016, 55, 4497-4499.	13.8	80
15	Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression. EBioMedicine, 2018, 28, 225-233.	6.1	74
16	Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. Journal of Clinical Investigation, 2021, 131 , .	8.2	70
17	Injectable MMP-Responsive Nanotube-Modified Gelatin Hydrogel for Dental Infection Ablation. ACS Applied Materials & Samp; Interfaces, 2020, 12, 16006-16017.	8.0	69
18	Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy. Bioconjugate Chemistry, 2018, 29, 771-775.	3.6	68

#	Article	IF	CITATIONS
19	A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. Analytical Chemistry, 2017, 89, 4838-4846.	6.5	64
20	Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC development I: In vitro evaluation. Journal of Controlled Release, 2016, 244, 302-313.	9.9	60
21	Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs. Nano Letters, 2020, 20, 7783-7792.	9.1	55
22	Highâ€Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis and Rheumatology, 2020, 72, 20-30.	5.6	51
23	Hybrid Antimicrobial Hydrogel as Injectable Therapeutics for Oral Infection Ablation. Biomacromolecules, 2020, 21, 3945-3956.	5.4	49
24	Microencapsulation of luteinizing hormone-releasing hormone agonist in poly (lactic-co-glycolic) Tj ETQq0 0 0 rg	gBT/J.gverlo	ock ₄₈ 0 Tf 50 5
25	Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas. Clinical Cancer Research, 2020, 26, 4369-4380.	7.0	48
26	Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1869-1878.	3.3	45
27	Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. Annals of the Rheumatic Diseases, 2017, 76, 602-611.	0.9	44
28	Systemic Delivery of an Adjuvant CXCR4–CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. ACS Nano, 2022, 16, 8729-8750.	14.6	43
29	Electrospinning of dexamethasone/cyclodextrin inclusion complex polymer fibers for dental pulp therapy. Colloids and Surfaces B: Biointerfaces, 2020, 191, 111011.	5.0	42
30	Reverse Engineering the 1-Month Lupron Depot®. AAPS Journal, 2018, 20, 105.	4.4	37
31	Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol. ELife, 2018, 7, .	6.0	37
32	Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™. MAbs, 2017, 9, 1197-1209.	5.2	36
33	Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. International Journal of Nanomedicine, 2016, Volume 11, 6229-6238.	6.7	34
34	Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers in Pharmacology, 2021, 12, 680021.	3.5	33
35	A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I. Journal of Biological Chemistry, 2017, 292, 20313-20327.	3.4	32
36	Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes. AAPS Journal, 2017, 19, 150-160.	4.4	30

#	Article	IF	CITATIONS
37	Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 107-116.	4.3	30
38	Structural analysis of lecithin:cholesterol acyltransferase bound to high density lipoprotein particles. Communications Biology, 2020, 3, 28.	4.4	30
39	Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas. Surgery, 2016, 159, 284-295.	1.9	29
40	Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma. International Journal of Nanomedicine, 2017, Volume 12, 6581-6594.	6.7	29
41	High-density lipoprotein-mimicking nanodiscs carrying peptide for enhanced therapeutic angiogenesis in diabetic hindlimb ischemia. Biomaterials, 2018, 161, 69-80.	11.4	29
42	Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma. International Journal of Molecular Sciences, 2020, 21, 1777.	4.1	26
43	Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport. Journal of Controlled Release, 2021, 329, 361-371.	9.9	25
44	Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization. Journal of Lipid Research, 2017, 58, 124-136.	4.2	24
45	HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. Frontiers in Endocrinology, 2018, 9, 715.	3.5	24
46	Validation of a cage implant system for assessing inÂvivo performance of long-acting release microspheres. Biomaterials, 2016, 109, 88-96.	11.4	23
47	Overview of Humira \hat{A}^{\otimes} Biosimilars: Current European Landscape and Future Implications. Journal of Pharmaceutical Sciences, 2021, 110, 1572-1582.	3.3	22
48	Apolipoprotein Mimetic Peptides for Stimulating Cholesterol Efflux., 2015,, 29-42.		22
49	<p>Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly</p> . International Journal of Nanomedicine, 2019, Volume 14, 3069-3086.	6.7	21
50	Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 146, 111-124.	4.3	21
51	Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 401-409.	4.3	21
52	Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases. BMC Medicine, 2019, 17, 200.	5.5	19
53	Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars. Analytical and Bioanalytical Chemistry, 2020, 412, 763-775.	3.7	19
54	Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics. Molecular Pharmaceutics, 2018, 15, 83-96.	4.6	18

#	Article	IF	Citations
55	Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 193-204.	2.5	17
56	Prospects of biological and synthetic pharmacotherapies for glioblastoma. Expert Opinion on Biological Therapy, 2020, 20, 305-317.	3.1	16
57	Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates. Journal of Controlled Release, 2021, 337, 168-178.	9.9	16
58	Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 2021, 74, 103725.	6.1	16
59	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 659-684.	4.1	15
60	Kr $\tilde{A}\frac{1}{4}$ ppel-like factor 14 deletion in myeloid cells accelerates atherosclerotic lesion development. Cardiovascular Research, 2022, 118, 475-488.	3.8	15
61	Replenishing HDL with synthetic HDL has multiple protective effects against sepsis in mice. Science Signaling, 2022, 15, eabl9322.	3.6	14
62	Reconstitution of the Cyt <i>>b</i> ₅ â€"CytP450 Complex in Nanodiscs for Structural Studies using NMR Spectroscopy. Angewandte Chemie, 2016, 128, 4573-4575.	2.0	13
63	Printing of small molecular medicines from the vapor phase. Nature Communications, 2017, 8, 711.	12.8	12
64	Infliximab Biosimilars in the Age of Personalized Medicine. Trends in Biotechnology, 2018, 36, 987-992.	9.3	12
65	Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice. Science Advances, 2020, 6, .	10.3	11
66	Robust Antiâ€Tumor T Cell Response with Efficient Intratumoral Infiltration by Nanodisc Cancer Immunotherapy. Advanced Therapeutics, 2020, 3, 2000094.	3.2	11
67	Artificial <scp>highâ€density lipoproteinâ€mimicking</scp> nanotherapeutics for the treatment of cardiovascular diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1737.	6.1	11
68	Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer. Surgery, 2019, 166, 1168-1175.	1.9	10
69	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. Frontiers in Oncology, 2021, 11, 631037.	2.8	10
70	The Effects of pH and Excipients on Exenatide Stability in Solution. Pharmaceutics, 2021, 13, 1263.	4.5	10
71	Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice. Frontiers in Pharmacology, 2020, 11, 513031.	3.5	10
72	Analytical method development and comparability study for AmBisome \hat{A}^{\otimes} and generic Amphotericin B liposomal products. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, 241-249.	4.3	10

#	Article	IF	CITATIONS
73	Collision-Induced Unfolding Reveals Stability Differences in Infliximab Therapeutics under Native and Heat Stress Conditions. Analytical Chemistry, 2021, 93, 16166-16174.	6.5	10
74	Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal. Surgery, 2018, 164, 165-172.	1.9	8
75	Streamlining the Characterization of Disulfide Bond Shuffling and Protein Degradation in IgG1 Biopharmaceuticals Under Native and Stressed Conditions. Frontiers in Bioengineering and Biotechnology, 2022, 10, 862456.	4.1	8
76	Nanodisc delivery of liver X receptor agonist for the treatment of diabetic nephropathy. Journal of Controlled Release, 2022, 348, 1016-1027.	9.9	8
77	Synthetic High-Density Lipoprotein (sHDL) Inhibits Steroid Production in HAC15 Adrenal Cells. Endocrinology, 2016, 157, 3122-3129.	2.8	5
78	Inkjet-printed micro-calibration standards for ultraquantitative Raman spectral cytometry. Analyst, The, 2019, 144, 3790-3799.	3.5	5
79	Synthetic high-density lipoprotein nanoparticles delivering rapamycin for the treatment of age-related macular degeneration. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 44, 102571.	3.3	5
80	Guest Editorial Title: Nanomedicine: past, present, and future. Advanced Drug Delivery Reviews, 2018, 130, 1-2.	13.7	1
81	NanoDDS 2017: The 15th International Nanomedicine & Drug Delivery Symposium. Journal of Controlled Release, 2018, 282, 1-2.	9.9	0
82	Reply. Arthritis and Rheumatology, 2020, 72, 1234-1236.	5.6	0
83	Abstract 448: The Association of 5A Peptide With Sphingomyelin Increases Its Ability to Efflux Cholesterol Both in vitro and in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	0